Apixaban may offer safety benefits over both rivaroxaban and warfarin in patients with cirrhosis and atrial fibrillation

A nationwide cohort study found that among patients with cirrhosis and nonvalvular atrial fibrillation (AF), initiating treatment with anticoagulant therapy, apixaban, may offer a safety benefit compared with rivaroxaban or warfarin. 

Read More